Citius Oncology, Inc. Price & Performance (CTOR)

Shareholders of TenX Keane Acquisition have approved a merger with Citius Pharmaceuticals’ oncology division, paving the way for the new Citius Oncology, Inc. Citius will retain about 90% ownership post-transaction. The move aims to boost commercialization of LYMPHIR, an immunotherapy candidate awaiting FDA review, and strengthen public market access.123

Several companies have undergone notable corporate actions: NYLI Cleaner Transport ETF and NYLI Clean Oceans ETF completed liquidations, crediting shareholders over $18 per share. SolarWinds Corporation and Altus Power executed cash mergers, while multiple firms, including MoneyLion and Vincerx Pharma, faced delistings or pending liquidations. These moves reflect ongoing volatility and consolidation in public markets.45

TenX Keane Acquisition shares have climbed over 8% recently, with the current price at $40.50 and sentiment indicators showing a bullish outlook. The merger with Citius Pharma’s oncology unit and positive technical trends suggest continued investor optimism, despite a high P/E ratio and notable volatility in recent trading sessions.631